Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1198 : TUHR4TKB  update : 2024/07/05
CommentJapanese renal carcinoma cells.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Kawai, Kouji & Ohno, Tadao
Originator Liu Shu Qin
Year of deposit 1996
Another name ToTe
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 60 years
Tissue kidney
Classification cancer
Year of origin 1995
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_5957
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/10 days, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Isozyme LD, NP
Chromosome mode 51-57(50) : /52(5),53(2),54(9),55(21),56(10),57(2)
STR(human) OK
Images
deposit info
lot info
Reference information Reference 4
User's Publication 15


To topTop
Reference
2442  Tsurushima H, Liu SQ, Tuboi K, Matsumura A, Yoshii Y, Nose T, Saijo K, Ohno T.  Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes  Jpn J Cancer Res  1999  90(5):536-45  PubMed ID: 10391094   DOI: 10.1111/j.1349-7006.1999.tb00781.x
4063  Liu SQ, Kawai K, Shiraiwa H, Hayashi H, Akaza H, Hashizaki K, Shiba R, Saijo K, Ohno T.  High rate of induction of human autologous cytotoxic T lymphocytes against renal carcinoma cells cultured with an interleukin cocktail.  Jpn J Cancer Res  1998  89(11):1195-201  PubMed ID: 9914789   DOI: 10.1111/j.1349-7006.1998.tb00515.x
1958  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads  Cytotechnology  1998  26(1):13-21  PubMed ID: 22359002   DOI: 10.1023/A:1007924430570
10450  S Q Liu, H Shiraiwa, K Kawai, H Hayashi, H Akaza, B S Kim, A Oki, M Nishida, T Kubo, K Hashizaki, K Saijo, T Ohno  Tumor-specific autologous cytotoxic T lymphocytes from tissue sections  Nat Med  1996  2(12):1283  PubMed ID: 8946818   DOI: 10.1038/nm1296-1283

To topTop
User's Publication
18231  Grubb T, Maganti S, Krill-Burger JM, Fraser C, Stransky L, Radivoyevitch T, Sarosiek KA, Vazquez F, Kaelin WG, Chakraborty AA.  A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer  Clin Cancer Res  2022  28(21):4689-4701  PubMed ID: 35776130   DOI: 10.1158/1078-0432.CCR-22-0669
20629  Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.  Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.  Proc Natl Acad Sci U S A  2022  119(14):e2120403119  PubMed ID: 35357972   DOI: 10.1073/pnas.2120403119
3742  Çubuk C, Hidalgo MR, Amadoz A, Rian K, Salavert F, Pujana MA, Mateo F, Herranz C, Carbonell-Caballero J, Dopazo J.  Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models.  NPJ Syst Biol Appl  2019  5:7  PubMed ID: 30854222   DOI: 10.1038/s41540-019-0087-2
10839  Tsuchida A, Senda M, Ito A, Saito S, Kiso M, Ando T, Harduin-Lepers A, Matsuda A, Furukawa K, Furukawa K.  Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells.  Sci Rep  2018  8:7017  PubMed ID: 29728594   DOI: 10.1038/s41598-018-25521-6
3741  Saleeb RM, Farag M, Lichner Z, Brimo F3, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM  Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.  Mol Oncol  2018  12(10):1673-1688  PubMed ID: 29896907   DOI: 10.1002/1878-0261.12346
3740  Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA.  Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.  Nat Commun. 2  2017  8:15165  PubMed ID: 28489074   DOI: 10.1038/ncomms15165
3745  Ning Z, Yongjing L, Yunzhen W, Zichuang Y, Qiang Z, Cheng W, Zhiqiang C, Yan X.  Optimization of cell lines as tumour models by integrating multi-omics data.  Brief Bioinform  2017  18(3):545  PubMed ID: 28013237   DOI: 10.1093/bib/bbw121
18235  Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T, Yamaguchi O, Kojima Y.  Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression  Eur J Cancer  2013  49(7):1715-24  PubMed ID: 23274199   DOI: 10.1016/j.ejca.2012.11.038
7606  Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M, Moriyama M.  Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma.  BMC Cancer  2011  11:523  PubMed ID: 22185343   DOI: 10.1186/1471-2407-11-523
8356  Hosono T, Tanaka T, Tanji K, Nakatani T, Kamitani T.  NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.  Br. J. Cancer  2010  102:873-82  PubMed ID: 20160729   DOI: 10.1038/sj.bjc.6605574
6387  Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, Okada Y, Okamoto K.  DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma.  Clin Cancer Res  2010  16(10):2751-9  PubMed ID: 20460473   DOI: 10.1158/1078-0432.CCR-09-3338
18947  Senda M, Ito A, Tsuchida A, Hagiwara T, Kaneda T, Nakamura Y, Kasama K, Kiso M, Yoshikawa K, Katagiri Y, Ono Y, Ogiso M, Urano T, Furukawa K, Oshima S, Furukawa K.  Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers  Biochem J  2007  402(3):459-70  PubMed ID: 17123352   DOI: 10.1042/BJ20061118
3396  Yamada, Daisuke, Kikuchi, Shinji, Williams, Yuko N, Sakurai-Yageta, Mika, Masuda, Mari, Maruyama, Tomoko, Tomita, Kyoichi, Gutmann, David H, Kakizoe, Tadao, Kitamura, Tadaichi, Kanai, Yae, Murakami, Yoshinori  Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.  Int J Cancer  2006  118:916-23  PubMed ID: 16152585   DOI: 10.1002/ijc.21450
5012  Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.  Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.  Hum Mol Genet  2006  15(6):821-30  PubMed ID: 16439445   DOI: 10.1093/hmg/ddl001
6450  Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T.  Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.  Oncol Rep  2004  12(4):805-10  PubMed ID: 15375503  


Back Back Return Top Page